Cefditoren is an orally active antibiotic with broad-spectrum antibacterial activity, capable of inhibiting both Gram-negative and Gram-positive bacteria. It has a MIC50 of 0.25-0.5 mg/L against Streptococcus pneumoniae strains. Cefditoren is effective against respiratory tract infections and skin infections[1][2][3].
ChEBI: A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the ce
hem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis,
ommunity-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.
[1] Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Cefditoren. 2023 Aug 15. PMID:30000384
[2] Giuliano S, et al. Cefditoren: a clinical overview. New Microbiol. 2023 Feb;46(1):9-17. PMID:36853812
[3] Sempere J, et al. A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004-20 in Spain. J Antimicrob Chemother. 2022 Mar 31;77(4):1045-1051. DOI:
10.1093/jac/dkab482
